A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02)

The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.

Study Overview

• Status: Not yet recruiting
• Conditions: Hormone Receptor Positive; Unresectable or Metastatic Breast Cancer; HER2-low or HER2-ultralow
• Intervention / Treatment: Drug: Patritumab deruxtecan; Drug: Trastuzumab deruxtecan

• Study Type: Interventional
• Enrollment (Estimated): 220
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Daiichi Sankyo Contact for Clinical Trial Information; Phone Number: 9089926400; Email: CTRinfo_us@daiichisankyo.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Key Inclusion Criteria:

1. Pathologically documented breast cancer that meets the following:

   1. Unresectable or metastatic.
   2. HR+ based on testing performed locally. HR+ (estrogen receptor [ER] and/or progesterone receptor [PgR] positive [ER or PgR greater than equal to (≥)1 percent (%)] per American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] 2020 guidelines) in the unresectable or metastatic setting.

   3. Assessed as HER2-low (defined as Immunohistochemistry (IHC)2+/In-situ hybridization (ISH)- or IHC1+) or HER2-ultralow (defined as IHC 0 with any membrane staining in greater than (>) 0 and lesser than equal to (≤)10% of the cancer cells) locally for Part 1 and centrally for Part 2. The HER2 result must be from a tumor sample obtained in the unresectable or metastatic setting.

      • For Dose Regimen Determination (Part 1), HER2 status used for eligibility assessment must be determined locally (according to applicable regulations) using the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.). Additional HER2 testing will be performed locally and according to applicable regulations using the prescribed test during Screening only if prior results obtained with this test are not available for eligibility assessment.
      • For Dose Expansion (Part 2), HER2 testing will be performed prospectively at a central laboratory using the pretreatment tumor tissue sample.

2. Provides a pretreatment tumor tissue sample that meets one of the following collection requirements:

   1. Tissue biopsy collected from ≥1 lesion not previously irradiated and performed since progression with the most recent systemic cancer therapy regimen and prior to signature of the Tissue Screening informed consent form (ICF) (ARCHIVAL PRETREATMENT sample).

      OR

   2. Newly obtained pretreatment tumor biopsy from ≥1 lesion not previously irradiated and amenable to sampling, after signature of the Tissue Screening ICF (FRESH PRETREATMENT sample).
3. Documented radiologic disease progression as per investigator assessment per RECIST v1.1 criteria (during or after most recent treatment).
4. Documented refractoriness to endocrine therapy, defined as disease progression on one or more line of endocrine therapy in the unresectable or metastatic setting and determined by the investigator that participant would no longer benefit from further treatment with endocrine therapy.
5. Prior treatment with a Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in any setting. Subsequent endocrine therapies administered after progression on CDK4/6 inhibitor are allowed.
6. Participants with genomic alterations/mutations (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA), phosphatase and tensin homolog (PTEN), AKT, or Breast Cancer gene (BRCA)1/2) who are eligible for approved targeted therapies in combination with endocrine therapy or as monotherapy (according to local label and availability) must have received the corresponding therapy prior to enrollment, unless contraindicated or not accessible in their country/region.
7. No prior chemotherapy for unresectable or metastatic breast cancer. Participants who have received chemotherapy in the neoadjuvant or adjuvant setting are eligible.
8. ECOG performance status 0 or 1 at the time of Screening.
9. Has ≥1 measurable lesion on CT or MRI per RECIST v1.1 by investigator assessment.
10. Has adequate bone marrow reserve and organ function based on local laboratory data within 7 days prior to the first dose as specified in the protocol.

Key Exclusion Criteria:

1. Prior treatment with an anti-HER3 antibody and/or antibody-drug conjugate (ADC) that consists of a topoisomerase I inhibitor (e.g., T-DXd) or any other topoisomerase I inhibitor therapy.
2. Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at Screening. Examples of suspected ILD/pneumonitis by imaging include the presence of lung parenchymal fibrosis, such as CPFE, and any radiographic features consistent with ILA, including but not limited to, extensive ground glass opacities, reticular opacities, traction bronchiectasis, and honeycombing. Participants may be eligible if they had history of radiation pneumonitis that did not require steroids.
3. Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone daily or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to randomization. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the trial.
4. Evidence of spinal cord compression or brain metastases, defined as being clinically active and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive or treated brain metastases who are asymptomatic (i.e., without neurologic signs or symptoms and do not require treatment with corticosteroids or anticonvulsants) may be included in the trial but must have a stable neurologic status for ≥4 weeks prior to Cycle 1 Day 1. Participants with asymptomatic brain metastases and treated with anticonvulsants as prophylaxis can enroll.

5. Inadequate washout period of prior treatment before randomization:

   1. Whole brain radiation therapy less than (<)28 days.
   2. Monoclonal antibodies other than immune checkpoint inhibitors, such as anti-vascular endothelial growth factor (VEGF) (e.g., bevacizumab) and anti-epidermal growth factor receptor (EGFR) (e.g., cetuximab) < 28 days.
   3. Immune checkpoint inhibitor therapy <21 days.
   4. Major surgery (excluding placement of vascular access) <28 days.
   5. Radiotherapy treatment to more than 30% of the bone marrow or wide field radiation or palliative stereotactic radiation to chest <28 days or palliative stereotactic radiation therapy to other anatomic areas <14 days.
   6. Chloroquine or hydroxychloroquine ≤14 days.
   7. Hormonal therapy <21 days prior to first dose of HER3-DXd.
   8. Live or live attenuated virus vaccination <30 days.

6. Uncontrolled or significant cardiovascular disease, including any of the following:

   1. QTcF prolongation interval >450 milliseconds (ms) (average of triplicate determinations at screening).
   2. Left ventricular ejection fraction (LVEF) ≤50%.
   3. Resting systolic blood pressure >160 millimeters of mercury (mmHg) or diastolic blood pressure >100 mmHg.
   4. Myocardial infarction within 6 months.
   5. New York Heart Association (NYHA) Classes 3 or 4 congestive heart failure.
   6. Uncontrolled angina pectoris within 6 months.
   7. Cardiac arrhythmia requiring ongoing antiarrhythmic treatment.
   8. Diagnosed or suspected long QT syndrome or known family history of long QT syndrome.
   9. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.
   10. Bradycardia of <50 beats per minute (bpm) unless the participant has a pacemaker.
   11. History of second- or third-degree heart block. Participants with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.
   12. Coronary/peripheral artery bypass graft within 6 months.
   13. Complete left bundle branch block.

7. Has history of other active malignancy within 3 years prior to randomization, except the following:

   1. Adequately resected nonmelanoma skin cancer.
   2. Adequately treated intraepithelial carcinoma of the cervix.
   3. Any other curatively treated in situ disease.
   4. Prostate carcinoma with a prostate-specific antigen value <0.2 nanograms per milliliter (ng/mL).
8. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0) Grade ≤1 or baseline.
9. Any known contraindication to treatment, including hypersensitivity to either the drug substances or inactive ingredients in the drug products.

Note: Other protocol specified inclusion/exclusion criteria may apply.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1: Arm 1: Dose Regimen Determination; Participants with unresectable or metastatic breast cancer (mBC) will receive T-DXd and HER3-DXd in combination regimen A until disease progression, death, unacceptable toxicity, or trial close.	Drug: Patritumab deruxtecan; Intravenous administration as determined by treatment arm.; Other Names: HER3-DXd; U31402; Drug: Trastuzumab deruxtecan; Intravenous administration as determined by treatment arm.; Other Names: T-DXd; DS8201a
Experimental: Part 1: Arm 2: Dose Regimen Determination; Participants with unresectable or mBC will receive T-DXd and HER3-DXd in combination regimen B until disease progression, death, unacceptable toxicity, or trial close.	Drug: Patritumab deruxtecan; Intravenous administration as determined by treatment arm.; Other Names: HER3-DXd; U31402; Drug: Trastuzumab deruxtecan; Intravenous administration as determined by treatment arm.; Other Names: T-DXd; DS8201a
Experimental: Part 2: Arm 3: Dose Expansion; Participants with unresectable or mBC will receive T-DXd and HER3-DXd in a combination regimen based on the available Part 1 data until disease progression, death, unacceptable toxicity, or trial close.	Drug: Patritumab deruxtecan; Intravenous administration as determined by treatment arm.; Other Names: HER3-DXd; U31402; Drug: Trastuzumab deruxtecan; Intravenous administration as determined by treatment arm.; Other Names: T-DXd; DS8201a
Active Comparator: Part 2: Arm 4: Monotherapy; Participants with unresectable or mBC will receive T-DXd monotherapy until disease progression, death, unacceptable toxicity, or trial close.	Drug: Trastuzumab deruxtecan; Intravenous administration as determined by treatment arm.; Other Names: T-DXd; DS8201a

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)	Adverse event(AE): any untoward medical occurrence in a participant administered pharmaceutical product (PP) and which does not necessarily have a causal relationship with the treatment.AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding, for example),symptom,or disease temporally associated with the use of PP, whether or not considered related to the PP.Pre-existing conditions which worsen during study are also considered as AEs.SAE:any AE that fulfilled any of following criteria:fatal,life-threatening,required inpatient hospitalisation or prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was congenital anomaly/birth defect, medically significant or required intervention to prevent any of the other outcomes listed here. TEAEs:AEs with start or worsening date during the on-treatment period(from 1st dose date of trial intervention to 47 days after the last dose date of trial intervention).	Up to approximately 4.5 years
Part 2: Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v.1.1) as Assessed by the Investigator	Objective response is defined as participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as assessed by investigator per RECIST v1.1.	Up to approximately 4.5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1: Objective Response Per RECIST v.1.1 as Assessed by the Investigator	Objective response is defined as participants with a BOR of confirmed CR or confirmed PR, as assessed by investigator per RECIST v1.1.	Up to approximately 6 years
Part 2: Number of Participants With at Least One TEAE and SAE	AE: any untoward medical occurrence in a participant administered pharmaceutical product (PP) and which does not necessarily have a causal relationship with the treatment.AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding, for example),symptom,or disease temporally associated with the use of PP, whether or not considered related to the PP.Pre-existing conditions which worsen during study are also considered as AEs.SAE:any AE that fulfilled any of following criteria:fatal,life-threatening,required inpatient hospitalisation or prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was congenital anomaly/birth defect, medically significant or required intervention to prevent any of the other outcomes listed here. TEAEs:AEs with start or worsening date during the on-treatment period(from 1st dose date of trial intervention to 47 days after the last dose date of trial intervention).	Up to approximately 6 years
Parts 1 and 2: Disease Control Per RECIST v.1.1 as Assessed by the Investigator	Disease control is defined as participants with a BOR of confirmed CR, confirmed PR, or SD per RECIST v1.1.	Up to approximately 6 years
Parts 1 and 2: Duration of Response (DoR) Per RECIST v.1.1 as Assessed by the Investigator	DoR is defined as the time (month) from date of initial response (CR or PR) to the earlier date of the first objective documentation of radiographic disease progression or death due to any cause.	Up to approximately 6 years
Parts 1 and 2: Clinical Benefit Per RECIST v.1.1 as Assessed by Investigator	Clinical benefit is defined as participants with a BOR of confirmed CR, confirmed PR, or SD lasting ≥183 days, per RECIST v1.1.	Up to approximately 6 years
Parts 1 and 2: Progression-free Survival (PFS) Per RECIST v.1.1 as Assessed by Investigator	PFS by investigator is defined as the time (month) from the date of randomization to the earlier date of the first objective documentation of radiographic disease progression as assessed by investigator per RECIST v1.1 or death due to any cause.	Up to approximately 6 years
Parts 1 and 2: Time to Response (TTR) Per RECIST v.1.1 as Assessed by Investigator	TTR is defined as the time (months) from the start date of study treatment to the date of the first documentation of response (CR or PR). TTR will be calculated for responders only.	Up to approximately 6 years
Parts 1 and 2: Overall Survival (OS)	OS is defined as the time (month) from the date of randomization to the date of death due to any cause.	Up to approximately 6 years
Part 1: Maximum Serum Concentration (Cmax) of Anti-HER3 Antibody Conjugate Deruxtecan (HER3-ac-DXd)		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Cmax of Total Anti-HER3 Antibody Liquid Chromatography-mass Spectrometry (LC-MS)		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Cmax of T-DXd		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Cmax of Total Anti-HER2 Antibody		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Cmax of Released Payload (DXd)		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Trough Serum Concentration (Ctrough) of Anti-HER3-ac-DXd		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Ctrough of Total Anti-HER3 antibody LC-MS		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Ctrough of T-DXd		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Ctrough of Total Anti-HER2 Antibody		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Ctrough of Released Payload (DXd)		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Time to Reach Maximum Serum Concentration (Tmax) of Anti-HER3-ac-DXd		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Tmax of Total Anti-HER3 Antibody LC-MS		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Tmax of T-DXd		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Tmax of Total Anti-HER2 Antibody		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Tmax of Released Payload (DXd)		Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 2: Correlation Between HER3 Protein Expression and Efficacy	HER3 protein expression in tumor tissue as determined by immunohistochemistry (IHC) and correlation with ORR, DoR, and PFS.	Up to approximately 6 years
Part 2: Correlation Between HER2 Protein Expression and Efficacy	HER2 protein expression in tumor tissue as determined by IHC and correlation with ORR, DoR, and PFS.	Up to approximately 6 years

Collaborators and Investigators

• Sponsor: Daiichi Sankyo
• Collaborators: Merck Sharp & Dohme LLC

Study record dates

Study Major Dates

• Study Start (Estimated): August 3, 2026
• Primary Completion (Estimated): January 1, 2031
• Study Completion (Estimated): May 1, 2032

Study Registration Dates

• First Submitted: July 8, 2026
• First Submitted That Met QC Criteria: July 8, 2026
• First Posted (Actual): July 14, 2026

Study Record Updates

• Last Update Posted (Actual): July 14, 2026
• Last Update Submitted That Met QC Criteria: July 8, 2026
• Last Verified: July 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Skin Diseases; Breast Diseases; Skin and Connective Tissue Diseases; Breast Neoplasms; trastuzumab deruxtecan; patritumab deruxtecan
• Other Study ID Numbers: U31402-287; 2024-517541-14-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
• IPD Sharing Time Frame: Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
• IPD Sharing Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No